Otsuka Pharmaceutical Development & Commercialization, Inc.

23 articles about Otsuka Pharmaceutical Development & Commercialization, Inc.

• Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder

  4/26/2023

  Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT 1A agonist activity, for the treatment of generalized anxiety disorder (GAD).

• Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer’s Dementia

  4/17/2023

  Otsuka Pharmaceutical Development & Commercialization, Inc., and Lundbeck Pharmaceuticals LLC announce the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. FDA met to discuss the supplemental New Drug Application of REXULTI® for the treatment of agitation associated with Alzheimer’s dementia.

• Otsuka Pharmaceutical and Lundbeck present positive results showing reduced agitation in patients with Alzheimer’s dementia treated with brexpiprazole at the 2022 Alzheimer's Association International Conference

  8/4/2022

  Results from a Phase 3 clinical study for treatment of agitation in patients with Alzheimer’s dementia showed that patients treated with brexpiprazole had a statistically significantly greater reduction in agitation compared to placebo Agitation is a very prevalent clinical manifestation in Alzheimer’s dementia and one of the most complex and stressful aspects of care in patients affected by the disease.

• Sunovion and Otsuka Initiate Phase 3 Clinical Development of Non-Racemic Amisulpride for the Treatment of People with Bipolar Depression

  2/9/2022

  Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in SEP380-301, a Phase 3 clinical study evaluating non-racemic amisulpride (SEP-4199) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression).

• 

  Top 10 Pharm Country Companies to Receive NIH Funding in 2020

  3/3/2021

  Across the Pharm Country Hotbed, the agency has provided hundreds of millions of dollars to universities, research institutes and pharmaceutical companies.

• Otsuka Pharmaceutical Development & Commercialization, Inc., and the Columbia University Mailman School of Public Health Enter Into a Global Pharmacovigilance Agreement

  11/24/2020

  Otsuka Pharmaceutical Development & Commercialization, Inc., and the Columbia University Mailman School of Public Health Enter Into a Global Pharmacovigilance Agreement PRINCETON, N.J. & NEW YORK--( BUSINESS WIRE )-- Otsuka Pharmaceutical Development & Commercialization, Inc., announced an agreement with research experts from the Columbia University Irving Center Vagelos College of Physicians and Surgeons and Mailman School of Public Health to

• Otsuka Pharmaceutical Development & Commercialization, Inc. Launches NephU, an Online Healthcare Community Dedicated to Kidney Health

  7/8/2020

  Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announces the launch of NephU ( www.nephu.org ) (formerly PKDnetwork), a community and online resource library designed for healthcare professionals working in nephrology (study of the kidney) to help engage, collaborate, and share resources for people living with kidney disease. NephU offers its members access to a growing on-demand library

• US Societal Economic Burden of an Inherited Kidney Disease Estimated at $7-10 Billion

  4/30/2020

  Analysis Group, Inc., a global leader in health economics and outcomes research, announced the publication of the first study of the direct and indirect costs of autosomal dominant polycystic kidney disease in the US.

• CORRECTING and REPLACING Sozosei Foundation Donates $439,000 to Support Those With Mental Health and Kidney Diseases

  4/24/2020

  Grants Distributed to Four Non-Profit Organizations Serving Patients, Healthcare Workers and Their Families Dealing with the Impact of COVID-19

• Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings

  5/2/2019

  Recent analyses highlight significant unmet clinical needs and burden of anemia due to chronic kidney disease

• Otsuka Pharmaceutical Development & Commercialization, Inc. Hosts Roundtable on Healthcare and Technology with U.S. Representative Bonnie Watson Coleman

  11/16/2018

  Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), a global leader in the development of digital and traditional treatments for mental illness, together with honorary co-host U.S. Representative Bonnie Watson Coleman (NJ-12) hosted a roundtable discussion of the expanding role of technology in the future of healthcare and its potential to break down barriers to care and support patient outcomes.

• 

  With a Bayer-Sanofi Executive Switch, Sanofi Creates Two New Global Business Units

  9/13/2018

  Paris-based Sanofi announced it is refocusing two of its international business units. The goal is to create more focus on mature markets and emerging markets.

• Science 37 and Otsuka Pharmaceutical Collaborate to Advance Digital Health Innovation With Focus on Technology-Enabled Clinical Trials at Home

  12/5/2017

  Dec. 5, 2017 13:00 UTC Science 37 and Otsuka Pharmaceutical Collaborate to Advance Digital Health Innovation with Focus on Technology-Enabled Clinical Trials at Home New collaboration between the tech-enabled clinical research company and US mental health leader aims to transform clinical trials to accelerate patient access to innovative therapies PLAYA VISTA, Calif. & ROCKVILLE, Md.--( BUSINESS WIRE )-- Science 3

• Otsuka to Host Web Briefing on Tolvaptan Phase III Trial Results in Polycystic Kidney Disease

  10/30/2017

  Otsuka Pharmaceutical Co. and its affiliate Otsuka Pharmaceutical Development & Commercialization are pleased to invite investors and media to a November 4 web briefing on in-depth results from the REPRISE phase 3 trial for tolvaptan

• Otsuka Pharmaceutical Development & Commercialization, Inc. And Lundbeck To Showcase Safety And Efficacy Data In Treatments For Challenging Mental Health Conditions

  9/13/2017

• Otsuka Pharmaceutical Development & Commercialization, Inc. And H. Lundbeck A/S Present Data At ACNP Annual Meeting On Long-Acting Injectable Aripiprazole As A Potential Maintenance Treatment For Bipolar I Disorder

  12/7/2016

• Otsuka Pharmaceutical Development & Commercialization, Inc. Release: FDA Approves Labeling Update Of REXULTI (brexpiprazole) For Maintenance Treatment Of Schizophrenia

  9/26/2016

• Otsuka Pharmaceutical Development & Commercialization, Inc. To Present Scientific Data At American Psychiatric Association Annual Meeting

  5/16/2016

• Otsuka Pharmaceutical Development & Commercialization, Inc. Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease

  6/11/2014

• Otsuka Pharmaceutical Development & Commercialization, Inc.'s Kidney Disease Drug Faces Setback

  8/30/2013